Cabozantinib inhibits AXL- and MET-dependent cancer cell migration induced by growth-arrest-specific 6 and hepatocyte growth factor.
AXL receptor tyrosine kinase
Cabozantinib
Cancer cell migration
Growth arrest-specific 6
Hepatocyte growth factor
MET proto-oncogene-encoded receptor tyrosine kinase
Journal
Biochemistry and biophysics reports
ISSN: 2405-5808
Titre abrégé: Biochem Biophys Rep
Pays: Netherlands
ID NLM: 101660999
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
26
09
2019
revised:
20
12
2019
accepted:
07
01
2020
entrez:
15
2
2020
pubmed:
15
2
2020
medline:
15
2
2020
Statut:
epublish
Résumé
Cabozantinib is known as an inhibitor of receptor tyrosine kinases mainly targeting AXL receptor tyrosine kinase (AXL),
Identifiants
pubmed: 32055714
doi: 10.1016/j.bbrep.2020.100726
pii: S2405-5808(19)30267-5
pii: 100726
pmc: PMC7005370
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100726Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors.
Déclaration de conflit d'intérêts
T.H., A.K., T.M, MM, K.N and J.S. are employed by Takeda; H.T. is employed by Axcelead.
Références
Mol Cancer. 2018 Feb 19;17(1):45
pubmed: 29455668
PLoS One. 2016 Apr 21;11(4):e0154186
pubmed: 27100677
Onco Targets Ther. 2018 Jan 23;11:509-519
pubmed: 29416351
Clin Cancer Res. 2008 Jan 1;14(1):130-8
pubmed: 18172262
Oncol Rep. 2017 Apr;37(4):2201-2208
pubmed: 28260071
Oncogene. 2016 May;35(21):2687-97
pubmed: 26364599
Curr Opin Cell Biol. 2014 Dec;31:98-105
pubmed: 25305631
Mol Med Rep. 2015 Jul;12(1):1485-92
pubmed: 25815442
Cancer Res. 2010 Oct 1;70(19):7570-9
pubmed: 20858715
Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
pubmed: 14685170
J Clin Oncol. 2009 Apr 1;27(10):1667-74
pubmed: 19255323
Clin Pharmacokinet. 2017 May;56(5):477-491
pubmed: 27734291
J Biol Chem. 2018 Oct 5;293(40):15397-15418
pubmed: 30108175
Mol Cancer Ther. 2011 Dec;10(12):2298-308
pubmed: 21926191
Mol Cancer. 2018 Jan 31;17(1):20
pubmed: 29386018
Mol Cancer Ther. 2018 Oct;17(10):2112-2122
pubmed: 30026382
Ann Transl Med. 2017 Jan;5(1):4
pubmed: 28164089
Oncotarget. 2017 Sep 8;8(43):75478-75487
pubmed: 29088883
Proc Natl Acad Sci U S A. 2014 Sep 16;111(37):13373-8
pubmed: 25187556
Nat Rev Cancer. 2014 Dec;14(12):769-85
pubmed: 25568918
Neoplasia. 2005 Dec;7(12):1058-64
pubmed: 16354588
Hepatology. 2018 Jan;67(1):216-231
pubmed: 28833396
Blood. 2010 Mar 18;115(11):2264-73
pubmed: 19965679
J Cancer. 2018 Sep 8;9(19):3427-3434
pubmed: 30310499
Mol Cancer Res. 2012 Jun;10(6):703-12
pubmed: 22516347
Br J Cancer. 2015 Aug 11;113(4):616-25
pubmed: 26180925
Clin Chem. 2007 Oct;53(10):1808-13
pubmed: 17717130